Studies have shown that in the context of ICIs, Tα1 exhibits the potential to enhance anti-tumor activity, while also improving safety and efficacy by regulating the differentiation and chemokine expression profile of DCs and inverting the CD8+: Treg ratio98. The gene discussed is TAAR1; the disease is neoplasm.